Drug Profile
BIWH 3
Alternative Names: MCP-1 - Boehringer Ingelheim; pyro-Glu-rhMCP-1Latest Information Update: 30 Oct 2021
Price :
$50
*
At a glance
- Originator Boehringer Ingelheim
- Class Anti-ischaemics; Recombinant proteins
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Peripheral ischaemia
Most Recent Events
- 21 Aug 2014 Discontinued - Phase-I for Peripheral ischaemia in Austria (IV)
- 21 Aug 2014 Discontinued - Phase-I for Peripheral ischaemia in Europe (IV)
- 21 Aug 2014 Discontinued - Phase-I for Peripheral ischaemia in USA (IV)